Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)
Thomas Ruhstaller(University Hospital Bonn), Viviane Hess(University Hospital of Bern), Miklos Pless(Ontario Institute for Cancer Research), Helmut Kranzbuehler(University of St.Gallen), Roger von Moos(Kantonsspital Graubünden), Michael Montemurro(University Hospital of Lausanne), Walter Mingrone(Kantonsschule Olten), Peter Moosmann(University of St.Gallen), Roman Inauen(University of St.Gallen), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Peter Brauchli(University of St.Gallen), Paul M. Schneider(Heidelberg University), Lucas Widmer(University of St.Gallen), Daniel Dietrich(University of St.Gallen), Daniel Rauch(Washington University in St. Louis)
Cited by 105
Related Papers
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
|Annals of Oncology|2019|1.4k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835